Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 1;96(7):E257-E259.
doi: 10.1002/ajh.26185. Epub 2021 Apr 24.

Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine

Evangelos Terpos  1 , Ioannis P Trougakos  2 , Filia Apostolakou  3 , Ioanna Charitaki  1 , Aimilia D Sklirou  2 , Nefeli Mavrianou  1 , Eleni-Dimitra Papanagnou  2 , Christine-Ivy Liacos  1 , Sentiljana Gumeni  2 , Gianna Rentziou  1 , Eleni Korompoki  1 , Ioannis Papassotiriou  3 , Meletios A Dimopoulos  1
Affiliations

Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine

Evangelos Terpos et al. Am J Hematol. .
No abstract available

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Anti‐Spike‐RBD and neutralizing antibodies (NAbs) against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. (A1) Anti‐Spike‐RBD IgG antibodies in donors of group one increased on D22 (day of second vaccination), reached a plateau 2 weeks after the second dose of the vaccine (D36; median U/mL for ages 25–50, 2500, and for ages 51–70, 1918.5) and started to decline at D50 (D50; median U/mL for ages 25–50, 1844, and for ages 51–70, 1319). The efficacy of the vaccine‐mediated anti‐Spike‐RBD IgG immune responses is age‐dependent as evident on both D22 (median U/mL for ages 25–50, 35.94; for ages 51–70, 17.36; and for octogenarians, 2.28) and on D50 (median U/mL for ages 25–50, 1844; for ages 51–70, 1319; and for octogenarians, 644.5). (A2) Development of anti‐Spike‐RBD IgG antibodies on D22 tended to be more intense in females vs males in the younger ages (males, median U/mL, 25.55; females, median U/mL, 31.46) and was significant in octogenarians (males, median U/mL, 0.793; females, median U/mL, 5.36). On D50, the noted difference for male vs female octogenarians (males, median U/mL, 526; females, median U/mL, 778) did not reach statistical significance. All positive for anti‐Spike‐RBD IgG antibodies participants on D1 have been removed (see text) to show only [n values in (A2)] the vaccine‐mediated effects; values are not paired with those shown in B. Median ages per group are reported in B,; for D1, D8 vs D36 or D50 in (A1) p < .001 (not indicated). (B) NAbs in donors of group 1 increased on D22, plateaued 2 weeks after the second dose of the vaccine (D36) [median NAbs (%) inhibition (all donors), 97.22] and remained (with a slight decline) at high levels on D50 [median NAbs (%) inhibition (all donors), 96.62] indicating that NAbs are likely more durable vs anti‐RBD IgGs (see A1) following BNT162b2 vaccination. On D22 the kinetics of accumulating NAbs (%) inhibition titers were age dependent as evident by comparing donors aged 25–50 [median NAbs (%) inhibition, 57.55] vs donors aged 51–70 (median NAbs (%) inhibition, 44.39) and for both age groups vs octogenarians (median NAbs (%) inhibition, 23.20); similar age‐dependent readouts were observed on D50. Immune responses tended to be more robust in females vs males reaching statistical significance on D22 and D50 in octogenarians, suggesting gender dependent humoral immune responses, at least in the elderly individuals. To demonstrate only the vaccine effect, all positive for NAbs donors (see text) on D1 have been removed. Shown n values denote the number of initially enrolled (negative for NAbs) participants in this on‐going study. For D1 or D8 vs D36, D50, p < .001 (not indicated). 25–50 years old.: ♂ Median Age: 39, ♀ Median Age: 39; 51–70 years old: ♂ Median Age: 60, ♀ Median Age: 59; 80–95 years old: ♂ Median Age: 84.5, ♀: Median Age: 85. In both A,B, * p ANOVA <.05, ** p‐ANOVA <.01, *** p‐ANOVA <.001, **** p‐ANOVA <.001). Plotted are Median values with 95% Confidence Interval (GraphPad Prism 7)
See this image and copyright information in PMC

References

    1. Trougakos IP, Stamatelopoulos K, Terpos E, et al. Insights to SARS‐CoV‐2 life cycle, pathophysiology, and rationalized treatments that target COVID‐19 clinical complications. J Biomed Sci. 2021;28(1):9. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383:2603‐2615. - PMC - PubMed
    1. Gharpure R, Patel A, Link‐Gelles R. First‐dose COVID‐19 vaccination coverage among skilled nursing facility residents and staff. JAMA. 2021;325(16):1670–1671. 10.1001/jama.2021.2352. - DOI - PMC - PubMed
    1. Tan CW, Chia WN, Qin X, et al. A SARS‐CoV‐2 surrogate virus neutralization test based on antibody‐mediated blockage of ACE2–spike protein–protein interaction. Nat Biotechnol. 2020;38(9):1073‐1078. - PubMed
    1. Rogers TF, Zhao F, Huang D, et al. Isolation of potent SARS‐CoV‐2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956‐963. - PMC - PubMed